Previous Next


№4' 2016


International Medical Journal, Vol. 22., Iss. 4, 2016, P. 57−62.


Lisovyi V. M., Dubinina H. M., Khareba H. H., Shchukin D. V.

Kharkiv National Medical University
V. I. Shapoval Kharkiv Regional Center of Urology and Nephrology, Ukraine

Prostate cancer is one of the most common forms of malignancy. An important parameter of its successful treatment is improvement of the quality of life of patients. With this purpose, the indicators of health−dependent quality of life of patients with metastatic hormone−naive prostate cancer treated with combination chemohormone therapy based on mitoxantrone, were investigated. FACT−P questionnaire was used as a research tool. The pain was characterized using an abridged version of BPI−SF questionnaire. The questionnaires were filled in 9, 20, 28 and 44 weeks after starting the course of treatment. Analysis of the results of investigation of health dependent quality of life showed advantages in patients of the group with combined chemohormone therapy at assessing the dynamics of the total score of four general domains and proportions of patients with noticeable improvement. These differences were statistically significant at week 28 and 44. The main advantages were recorded in the domains of «social condition» and «emotional condition» at all time points. Dynamics of the mean score of pain, as well as analysis of the proportion of patients reported improvement according to the BPI questionnaire, showed distinct priorities of combination chemohormone therapy during the observation period.

Key words: disseminated hormone−naive prostate cancer, chemohormone therapy, androgen deprivation therapy, mitoxantrone, health−dependent quality of life.

Go on Top